

Org #556966-4955  
Date: May 24, 2021



THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT IN WHOLE OR IN PART TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ELICERA THERAPEUTICS AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.

## Elicera Therapeutics' first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Gothenburg, Sweden May 24, 2021 - Elicera Therapeutics, a clinical stage cell and gene therapy company that develops immuno-oncological treatments focusing on CAR T cells and oncolytic viruses, announces that the subscription period for the company's new share issue prior to the planned listing on Nasdaq First North Growth Market begins today and runs until June 8. The new share issue consists of a directed issue of a maximum of 6,500,000 Units, each consisting of one (1) new share and one (1) new free warrant of series TO 1. Upon full subscription in the Offer, Elicera will receive SEK 52.0 million before issue costs, and upon full exercise of the warrants included in the Offer, the Company will in November 2022 receive an additional SEK 37.7 million before issue costs.

*"Elicera is now entering a new development phase for both our next generation CAR-T and oncolytic virus candidates with an increased focus on clinical studies. The impending capital raise and the planned market listing of the shares give us the opportunity to effectively advance our drug candidates towards patient studies and better opportunities to expose our business to healthcare, capital markets and industry",* comments Elicera's CEO, Jamal El-Mosleh

### Company highlights

- **Approaching clinic with 4<sup>th</sup> generation CAR-T therapies** for enhanced treatment of solid and non-solid tumors. First movers in new space with majority of companies still working on 2<sup>nd</sup> generation.
- **Deploying a fully developed technology platform called iTANK** that generates CAR T-cells with a second mode of action to inhibit tumor growth and prolong survival compared to conventional CAR-T cells
- **Next generation Oncolytic Virus candidates** under development combining three modes-of-action for multiple cancer indications.
- **Strong intellectual property** through patents granted, licenced, or pending for all key assets, including drug candidates and iTANK platform

- **Strong management team and Board** with in-depth experience in the immunotherapy field and of managing fast-growing companies and building asset value through collaborations and licensing deals.

### **Reason for the Offering**

The Board of Directors has decided to implement this Offering to ensure continued successful development in accordance with the Company's business plan and strategy. The purpose of the Offering is primarily to finance the development of the four pharmaceutical projects for preclinical and clinical studies, of which ELC-100 is most advanced.

If the Offering is fully subscribed, the Company will receive approximately SEK 46.7 million less issue costs of approximately SEK 5.3 million. If the offering is heavily oversubscribed, the Board of Directors has the option to issue an additional 1,250,000 Units corresponding to SEK 10 million through a directed issue. Elicera intends to use the net proceeds for the following purposes listed in order of priority:

- Further development of the ELC-100 and ELC-201
- Further development of ELC-301 and ELC-401
- General development work
- Bolster working capital and administration

### **Subscription of the share**

Subscription will be possible through Nordnet and Avanza, as well as the banks/managers that enable their customers to subscribe in the issue. Subscription ends June 8. It should be noted that different banks may have an earlier day and time for the last day to register for participation in the issue.

### **Prospectus and more information**

Complete terms and conditions for the Offer and information about Elicera can be found in the prospectus that has been published and is available on Elicera's website <https://www.elicera.com/nav/disclaimer-ipo-2021>

### **For further information please contact:**

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51

[jamal.elmosleh@elicera.com](mailto:jamal.elmosleh@elicera.com)

### **About Elicera Therapeutics AB**

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera

has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer.

For more information, please visit [www.elicera.com](http://www.elicera.com)

## Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in Elicera. The invitation to interested persons to subscribe for shares and warrants in Elicera will only be made through the prospectus that Elicera published May 21, 2021. No action has been, or will be taken, by Elicera to allow an offer to the public in jurisdictions other than Sweden. This press release may not be published, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, South Korea, Switzerland, Singapore or the United States or any other jurisdiction where such action is subject in whole or in part to legal restrictions, or would require additional prospectuses, registration or other measures than what is required by Swedish law. The information contained in this press release may also not be transmitted or reproduced in ways that are contrary to such restrictions or would entail such requirements. Measures contrary to this instruction may constitute a breach of applicable securities laws. New shares and warrants subscribed for in the Offering have not been and will not be registered under the United States Securities Act of 1933 as amended (the "Securities Act") and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or into the United States, except under an applicable exemption from the registration requirements of the Securities Act. The Offer is also not addressed to persons domiciled in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, South Korea, Switzerland, Singapore or in any other jurisdiction where participation would require additional prospectuses, registration or other measures than those under Swedish law.